The NavDx ® blood test analyzes tumor tissue modified viral (TTMV)-HPV DNA to provide a reliable means of detecting and monitoring HPV-driven cancers. The test has been clinically validated in a large number of independent studies and has been integrated into clinical practice by over 1000 healthcare providers at over 400 medical sites in the US.
HPV6 and HPV11 are the types known to cause genital warts. Of all of these, two are known to cause the majority of cancers. These two strains are HPV16 and HPV18. When genotyping is performed, it provides the doctor with information as to just which strains of HPV you may have and thereby the ability to assess your particular risk for
Finally, a subset of eight HPV-negative tumors were tested for the presence of high-risk-HPV E7 DNA using a sensitive E7 multiplex PCR, enabling the detection of 14 high-risk-HPV types (16, 18, 31
The test will show if it found types of HPV that could cause cancer. The results may be: Negative. This means that the test didn't find HPV types that could cause cancer. Or this means it found only types that carry a low risk for cancer. Positive. This means the test found at least 1 HPV type that could cause cancer.
For women with a positive oncogenic HPV (not 16/18) test result and a cytological prediction of LSIL, the risk of CIN3+ was lower than that for the 12-month follow-up benchmark (LSIL cytology, regardless of HPV status): over 2 years in cohorts age >18 years or >30 years at baseline. after 18 years in a cohort age >16 years at baseline.
DNA-ISH for HPV. HPV DNA was detected by ISH by the CCHMC Pathology Research Core 74. In brief, a chromogenic ISH test for high-risk HPV genomes, including HPV16, was performed (Ventana Medical
